Table 3.

Effects of treatment group assignment on AIDS Risk Behaviors (N=126)

	Buprenorphine			Naltrexone			Placebo
	Baseline	3-month	6-month	Baseline	3-month	6-month	Baseline	3-month	6-month	Time effect	Medication effect	Interaction
	n=41	n=42	n=36	n=42	n=30	n=29	n=39	n=29	n=23	p	p	p
ARI total score Mean (95%CI)	56.5(48.0–64.9)	47.3(41.7–53.0)	53.7(44.1–63.4)	46.4(37.9–54.0)	43.7(36. 7–50.6)	43.1(33. 5–52.7)	57.0(46.7–67.1)	47.4(39.5–55.3)	43.6(34.9–52.4)	<0.01	0.138	0.321
ARI drug risks subscore Mean (95% CI)	38.9(32.7–45.1)	23.1(19.3–26.8)	25.0(20.2–29.8)	30.4(24.0–36.8)	22.5(18.3–26.8)	21.8(16.5–27.1)	41.3(34.2–48.3)	26.4(22.0–30.8)	25.8(20.0–31.7)	<0.001	0.13	0.276
ARI sex risks subscore Mean (95% CI)	15.4(11.7–19.0)	15.0(11.7–18.3)	19.1(15.7–22.6)	11.7(8.1–15.4)	11.5(7.9–15.2)	14.4(10.6–18.2)	13.4(9.4–17.3)	12.0(8.0–16.0)	14.2(9.8–18.6)	0.136	0.193	0.983
IDU past 30 days n/N (%)	20/41(49%)	1/42(2.4%)	5/36(14%)	16/42(38%)	2/30(6.7%)	2/29(6.9%)	16/39(41%)	2/29(6.9%)	2/23(8.7%)	<0.001	0.716	0.669